Close

Zynext Ventures Invests in Promaxo: Revolutionizing Point-of-Care Imaging with Advanced MRI Technology

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

NHS Life Sciences Sector Plan Accelerates Innovation in UK

The UK Government’s NHS Life Sciences Sector Plan is...

Cleveland Clinic London Cancer Centre Expansion Announced

Cleveland Clinic London Cancer Centre will  expand an 81,000-square-foot...

EHR Health IT Solutions Among Others Impacting Patient Fate

EHR Health IT solutions and also telehealth platforms, patient...

EHRA asks HHS to Modernizing the Regulatory Approach to RFI

The HIMSS Electronic Health Record Association in the US...

Zynext Ventures USA LLC, the venture capital division of Zydus Lifesciences, has made an investment in Promaxo Inc., an innovator in portable low-field MRI systems and minimally invasive robotics.

Promaxo’s technology is set to transform patient care by enabling point-of-care imaging and intervention.

Their portable MRI system, which has received FDA 510(k) clearance for prostate biopsy and treatment, features a compact and open design with minimal fringe field.

This design allows for installation in a variety of healthcare settings, including clinics and operating rooms.

Additionally, Promaxo is working towards FDA clearance for its own robotic system, which aims to enhance precision in prostate interventions.

The investment reflects Zydus Lifesciences’ commitment to advancing healthcare innovations that address unmet needs.

Promaxo’s integration of accessible MRI technology with robotics for guided interventions is expected to improve patient outcomes and expand access to critical point-of-care imaging.

The National Cancer Institute (NCI) reports approximately 3.3 million men in the US living with prostate cancer, with around 300,000 new cases projected for 2024.

The market for prostate biopsy and treatment in the US is valued at approximately $3 billion, with around one million biopsies performed annually.

Promaxo is also looking to expand into other areas such as female pelvic, kidney, breast, and orthopedic imaging.

Latest stories

Related stories

NHS Life Sciences Sector Plan Accelerates Innovation in UK

The UK Government’s NHS Life Sciences Sector Plan is...

Cleveland Clinic London Cancer Centre Expansion Announced

Cleveland Clinic London Cancer Centre will  expand an 81,000-square-foot...

EHR Health IT Solutions Among Others Impacting Patient Fate

EHR Health IT solutions and also telehealth platforms, patient...

EHRA asks HHS to Modernizing the Regulatory Approach to RFI

The HIMSS Electronic Health Record Association in the US...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back